Results 11 to 20 of about 18,746 (183)
Brain and Behavior, 2021 Background Visual hallucinations are common in patients with Parkinson's disease and represent probably the major independent predictor for cognitive deterioration and nursing home placement.
Tom J. M. vanMierlo +10 more
doaj +1 more source
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]
, 2015 This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Abagyan, Ruben +4 more
core +3 more sources
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial [PDF]
, 2017 BACKGROUND/OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to ...
Boustani, Malaz A. +8 more
core +1 more source
PLoS ONE, 2023 BackgroundRivastigmine is a pseudo-irreversible cholinesterase inhibitor used for therapy of Alzheimer's disease and non-Alzheimer dementia syndromes. In humans, rivastigmine can cause significant gastrointestinal side effects that can limit its clinical
Chrysostomi Christina Tsianou +10 more
doaj +1 more source
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019 Introduction The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until ...
Chee‐Jen Chang +9 more
doaj +1 more source
International Journal of Gerontology, 2016 Rivastigmine is a well-known dual acting acetylcholinesterase and butyrylcholinesterase inhibitor, which is effective on behavioral and psychiatric symptoms including hallucinations, as well as cognitive symptoms of dementia.
Yıldız Değirmenci, Hulusi Keçeci
doaj +1 more source
A survey of substance use for cognitive enhancement by university students in the Netherlands [PDF]
, 2015 Background: Pharmacological cognitive enhancement, using chemicals to change cellular processes in the brain in order to enhance one's cognitive capacities, is an often discussed phenomenon.
Bundt, Carsten +5 more
core +3 more sources
Dementia and Geriatric Cognitive Disorders Extra, 2011 Background: Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer’s disease (AD). Methods: AD patients who participated in a randomized, double-blind, placebo-controlled trial of rivastigmine patch and capsule treatment were ...
M.R. Farlow +4 more
doaj +1 more source
Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. [PDF]
PLoS ONE, 2017 To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment.We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot trial ...
Jose A Muñoz-Moreno +10 more
doaj +1 more source
Frankincense Upregulates the FMR1 Gene and Alleviates AlCl3-Induced Memory Impairment in Rats [PDF]
Journal of Genetic Resources, 2021 Alzheimer's disease (AD) is a multifactorial disorder that its progress and development are related to various genetic and environmental factors.
Mohammad Khalaj-Kondori +2 more
doaj +1 more source